Literature DB >> 15496199

Characterization and functional study of five novel monoclonal antibodies against human OX40L highlight reverse signalling: enhancement of IgG production of B cells and promotion of maturation of DCs.

Q Wang1, Y Chen, Y Ge, J Sun, Q Shi, S Ju, J Dai, G Yu, X Zhang.   

Abstract

OX40 ligand (OX40L), a molecule originally identified as human gp34, is an important co-stimulatory molecule during immune response. In this study, we report on five functional mouse anti-human OX40L monoclonal antibodies named as 9H10, 4C12, 8D10, 4H4 and 1G1, characterized by means of flow cytometry, Western blot and competition assay. These monoclonal antibodies bound to distinct OX40L epitopes on activated B cells and dendritic cells (DCs) and two of them could suppress the proliferation of T lymphocytes co-stimulated by mature DCs. Furthermore, we demonstrated that our monoclonal antibodies, such as 9H10 and 4C12, could trigger OX40L reverse signal that enhanced IgG production of B cells and promoted maturation of DCs as evidenced by the upexpression of CD80, CD86, CD83 and CXCR4 and monoclonal antibody 9H10 could also promote anti-CD40 monoclonal-antibody-stimulated DCs in order to induce T cells to secrete more interleukin-2 and interferon-gamma, which suggested that OX40L signals could strengthen the effect of CD40 signals on promoting Th1 differentiation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15496199     DOI: 10.1111/j.1399-0039.2004.00300.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  9 in total

1.  OX40 Cooperates with ICOS To Amplify Follicular Th Cell Development and Germinal Center Reactions during Infection.

Authors:  Vikas Tahiliani; Tarun E Hutchinson; Georges Abboud; Michael Croft; Shahram Salek-Ardakani
Journal:  J Immunol       Date:  2016-11-28       Impact factor: 5.422

Review 2.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 3.  Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity.

Authors:  Takanori So; Seung-Woo Lee; Michael Croft
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

Review 4.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 5.  Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents.

Authors:  Takahiko Horiuchi; Hiroki Mitoma; Shin-ichi Harashima; Hiroshi Tsukamoto; Terufumi Shimoda
Journal:  Rheumatology (Oxford)       Date:  2010-03-01       Impact factor: 7.580

6.  Blockade of OX40-ligand after initial triggering of the T helper 2 response inhibits mercuric chloride-induced autoimmunity.

Authors:  Iain A M MacPhee; Hideo Yagita; David B G Oliveira
Journal:  Immunology       Date:  2006-03       Impact factor: 7.397

7.  Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis.

Authors:  Julie K Laustsen; Tue K Rasmussen; Kristian Stengaard-Pedersen; Kim Hørslev-Petersen; Merete L Hetland; Mikkel Østergaard; Peter Junker; Malene Hvid; Bent Deleuran
Journal:  Arthritis Res Ther       Date:  2014-10-30       Impact factor: 5.156

Review 8.  Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy.

Authors:  Sebastian Chrétien; Ioannis Zerdes; Jonas Bergh; Alexios Matikas; Theodoros Foukakis
Journal:  Cancers (Basel)       Date:  2019-05-05       Impact factor: 6.639

9.  OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis.

Authors:  Emily Gwyer Findlay; Lynett Danks; Jodie Madden; Mary M Cavanagh; Kay McNamee; Fiona McCann; Robert J Snelgrove; Stevan Shaw; Marc Feldmann; Peter Charles Taylor; Nicole J Horwood; Tracy Hussell
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.